BlossomHill Therapeutics Unveils Next-Generation Pan-KRAS Inhibitors with Picomolar Potency at AACR 2026
核心洞察
BlossomHill Therapeutics (搜索) announced two novel non-covalent pan-KRAS (搜索) inhibitors, BH-501284 (搜索) and BH-501242 (搜索), featuring sub-nanomolar potency and prolonged off-rates to address limitations of existing KRAS therapies.
The lead compound BH-501284 (搜索) demonstrates picomolar binding affinity and durable tumor regression across multiple cancer types including NSCLC, colorectal cancer (搜索), and pancreatic ductal adenocarcinoma (搜索).
The company will present comprehensive preclinical data at AACR 2026, including results from their clinical-stage programs BH-30643 for EGFR (搜索)-mutated cancers and BH-30236 for hematologic malignancies.
BlossomHill Therapeutics (搜索) announced the introduction of its next-generation KRAS (搜索) inhibitor pipeline at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2026, featuring two novel non-covalent pan-KRAS inhibitors designed to overcome limitations of contemporary molecules. The San Diego-based clinical-stage biopharmaceutical company will present preclinical data demonstrating sub-nanomolar potency and prolonged off-rates combined with oral bioavailability.
"KRAS (搜索) remains one of the most important and historically difficult targets in oncology," said Jean Cui, Ph.D., Founder and Chief Executive Officer of BlossomHill Therapeutics (搜索). "Our next-generation pan-KRAS inhibitors are intentionally designed using a differentiated chemical scaffold to deliver pseudo-irreversible target engagement and improved drug-like properties we believe will translate to clinical impact."
Novel Pan-KRAS Inhibitors Target Multiple Cancer Types
The company's lead pan-KRAS (搜索) compound, BH-501284 (搜索), demonstrates picomolar binding affinity and broad activity across KRAS mutations, showing durable tumor regression in non-small cell lung cancer (搜索) (NSCLC), colorectal cancer (搜索) (CRC), and pancreatic ductal adenocarcinoma (搜索) (PDAC) models. By preferentially targeting inactive KRAS and maintaining activity under growth factor-driven resistance conditions, BH-501284 may overcome key limitations of existing KRAS inhibitors.
The second compound, BH-501242 (搜索), targets the KRAS (搜索) switch II pocket and potently inhibits a broad range of KRAS mutations, including G12D, G12V, and G12C, with sub-nanomolar cellular activity and robust tumor regression in multiple xenograft models. Its ability to bind both active and inactive KRAS and achieve strong oral exposure supports further development as a differentiated, mutation-agnostic KRAS therapy.
Clinical Pipeline Advances with Combination Strategies
BlossomHill will also present new preclinical data supporting the continued advancement of its clinical programs. BH-30236, a novel oral CLK1/2/4 inhibitor, modulates alternative splicing to induce apoptosis and suppress leukemia stem cell-associated pathways, demonstrating robust anti-leukemia activity in acute myeloid leukemia (搜索) (AML) and chronic lymphocytic leukemia (搜索) (CLL) models.
In combination studies, BH-30236 synergized with venetoclax to produce synergistic tumor regression, including durable, complete responses in resistant xenograft models. The CLK (搜索) inhibitor is being developed for the treatment of relapsed or refractory acute myeloid leukemia (搜索) (R/R AML) or higher-risk myelodysplastic syndrome (搜索) (HR-MDS), representing a first-in-class opportunity.
EGFR Inhibitor Overcomes Resistance Mutations
The company's EGFR (搜索) program, BH-30643, is a macrocyclic, non-covalent, mutant-selective OMNI-EGFR inhibitor that uniquely overcomes T790M and C797S resistance mutations while maintaining potent activity against classical EGFR drivers and sparing wildtype EGFR. In preclinical studies, BH-30643 demonstrated prolonged suppression of tumor cell proliferation compared to osimertinib, including under growth factor-mediated resistance conditions.
BH-30643 is being developed for the treatment of EGFR (搜索)- or HER2-mutated non-small cell lung cancer (搜索) (NSCLC) and represents a first-in-class approach to addressing resistance limitations of contemporary EGFR tyrosine kinase inhibitors.
Company Background and Leadership
BlossomHill Therapeutics (搜索) is led by industry veteran J. Jean Cui, Ph.D., who has a proven track record in oncology drug design and development, including three FDA-approved drugs. The company applies cutting-edge science to address key oncogenic drivers and improve patient outcomes in difficult-to-treat cancers.
The privately held company has raised a total of $257 million from leading life sciences investors and is headquartered in San Diego, California. The AACR Annual Meeting 2026 will be held April 17-22, 2026, in San Diego, where BlossomHill will present four presentations across multiple sessions, including a minisymposium highlighting their BH-501284 (搜索) program.